30 closest matches · ranked by relevance
Venezuelan Equine Encephalitis · Western Equine Encephalitis · Eastern Equine Encephalitis
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms For 7 Days After Each Product Administration — 4; 2; 0; 1 Participants
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Recurrent Melanoma · Stage IV Melanoma
Primary: Tumor Response — 0; 0 participants
Healthy Volunteers · Norovirus, Prevention
Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) — 43.3; 62.1; 46.4; 35.5 percentage of participants
Influenza
Primary: Hemagglutination Inhibition Antibody (HIA) Titer for Each of the Three Antigens Contained in the Vaccine — 269.7; 337.3; 288.5; 297.1 Titers
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
Anaplastic Astrocytoma · Anaplastic Oligodendroglioma · Mixed Glioma
Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…
Covid19
Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants
Gastroenteritis
Primary: Number of Participants With Solicited Local Adverse Events (AEs) Post Dose 1 — 4; 5; 6; 5 participants
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Influenza · Vaccine Virus Shedding
Primary: Number of Participants Shedding Each Vaccine Virus Measured by qPCR of Nasosorption Samples — 31 participants
Norovirus Prevention
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After the First Injection — 7.8; 64.1; 72.7; 7.8 percentage of participants
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases
Primary: Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza Strains — 118; 130 Number of cases
Enterovirus Infection · Type 1 Diabetes · Prediabetic State
Primary: Number of Participants With the Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum — 17; 2 Participants
Norovirus
Primary: Percentage of Participants With a Seroresponse (Pan-Ig ELISA) in Cohort 1 — 77.4; 63.5; 74.5; 85.7 percentage of participants
Rotavirus Infection
Primary: Number of Participants Developing a Serum Anti-rotavirus Immunoglobulin (Ig) A Titer of 20 or Greater in the WC3 IgA Assay — 186; 182; 175; 191 participants
Influenza A Subtype H5N1 Infection
Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants
Norovirus Infections
Primary: Number of Participants With Solicited Symptoms of Reactogenicity (Gastrointestinal [GI] and Systemic) — 20; 20; 2; 9 Participants
HIV Infection
Primary: Grade 3 Adverse Event Related to DermaVir Treatment — 0; 0; 0 participants
Japanese Encephalitis
Primary: Primary: Plasmablast Percentage of Total B Cells at 7 Days Post Vaccine — 1.36; 1.96; 1.69 percent plasmablasts of B cells
Norovirus · Healthy Participants
Primary: Number of Participants With Serum Samples Obtained on Day 8 for Assessment of Seropositivity for Both Anti-NoV GI.1 VLP and GII.4 VLP Antibodies — 48 participants
Influenza
Primary: Number of Participants Who Shed Virus — 0 participants
Herpes Zoster
Primary: Number of Participants Who Received Zostavax Immunization or Had Natural Exposure to VZV — 45; 9 Participants
Norovirus
Primary: Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by…
Influenza Vaccines
Primary: Geometric Mean Titers (GMTs) of Anti-H3 and B Strains — 369.6; 331.2; 269.6; 245.0 Titer
Smallpox Vaccine Adverse Reaction
Primary: Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration — 52; 8; 4 percentage of participants
Rabies · Healthy Volunteers
Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to (>=) 0.5 IU/mL — 100; 100; 100; 100…
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants